Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3

AIDS Research and Therapy

Volumn 4, Issue , 2007, Pages

  Manosuthi, Weerawat ^a   Chimsuntorn, Sukanya ^a   Likanonsakul, Sirirat ^a   Sungkanuparph, Somnuek ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; HEMOGLOBIN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; RNA; STAVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; URTICARIA;

EID: 33947538305     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-4-6     Document Type: Article

References (29)

1. Hammer SM Saag MS Schechter M Montaner JS Schooley RT Jacobsen DM Thompson MA Carpenter CC Fischl MA Gazzard BG Gatell JM Hirsch MS Katzenstein DA Richman DD Vella S Yeni PG Volberding PA Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel Jama 2006 296 7 827-843 10.1001/jama.296.7.827 16905788
2. Gazzard B British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005) HIV Med 2005 6 Suppl 2 1-61 10.1111/j.1468-1293.2005.0311b.x 16011536
3. Ferrer E Santamarina E Domingo P Fumero E Ribera E Knobel H Lopez JC Barrios A Podzamczer D Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less Aids 2004 18 12 1727-1729 10.1097/01.aids.0000131381.07609.19 15280785
4. Murphy RL Sommadossi JP Lamson M Hall DB Myers M Dusek A Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1 J Infect Dis 1999 179 5 1116-1123 10.1086/314703 10191212
5. van Leth F Phanuphak P Ruxrungtham K Baraldi E Miller S Gazzard B Cahn P Lalloo UG van der Westhuizen IP Malan DR Johnson MA Santos BR Mulcahy F Wood R Levi GC Reboredo G Squires K Cassetti I Petit D Raffi F Katlama C Murphy RL Horban A Dam JP Hassink E van Leeuwen R Robinson P Wit FW Lange JM Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study Lancet 2004 363 9417 1253-1263 10.1016/S0140-6736(04)15997-7 15094269
6. Authar RS Sankote J Mahanontharit A Ubolyam S Giel D Cooper D Lange J Phanuphak P Burger D Ruxrungtham K Results from pilot quality control program of generic antiretrovirals: Content and dissolution analysis of generic nevirapine (HIV-NAT026).: 24-27 July 2005; Rio de Janeiro. TUPeB4606 2006, TuPe3.1B02
7. WHO Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: Towards universal access: Towards universal access. Geneva: World Heath Organization; 2006 revsion. Available at http://www.who.int/hiv 2006 revision 2097487
8. Calmy A Pinoges L Szumilin E Zachariah R Ford N Ferradini L Generic fixed-dose combination antiretroviral treatment in resource-poor settings: Multicentric observational cohort Aids 2006 20 8 1163-1169 10.1097/01.aids.0000226957.79847.d6 16691068
9. Pollard RB Robinson P Dransfield K Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection Clin Ther 1998 20 6 1071-1092 10.1016/ S0149-2918(98)80105-7 9916603
10. Fagot JP Mockenhaupt M Bouwes-Bavinck JN Naldi L Viboud C Roujeau JC Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis Aids 2001 15 14 1843-1848 10.1097/00002030-200109280-00014 11579247
11. Metry DW Lahart CJ Farmer KL Hebert AA Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine J Am Acad Dermatol 2001 44 2 Suppl 354 357 10.1067/mjd.2001.101885 11174414
12. Bourezane Y Salard D Hoen B Vandel S Drobacheff C Laurent R DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy Clin Infect Dis 1998 27 5 1321-1322 9827291
13. Lanzafame M Rovere P De Checchi G Trevenzoli M Turazzini M Parrinello A Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy Scand J Infect Dis 2001 33 6 475-476 10.1080/ 00365540152029990 11450872
14. Anekthananon T Ratanasuwan W Techasathit W Sonjai A Suwanagool S Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: A 24-week study J Med Assoc Thai 2004 87 7 760-767 15521230
15. Tin EE Bowonwatanuwong C Desakorn V Wilairatana P Krudsood S Pitisuttithum P The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naive adult HIV patients Southeast Asian J Trop Med Public Health 2005 36 2 362-369 15916042
16. Sungkanuparph S Kiertiburanakul S Manosuthi W Kiatatchasai W Vibhagool A Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: Efficacy and tolerability Int J STD AIDS 2005 16 3 243-246 10.1258/0956462053420121 15829026
17. Powderly WG Saag MS Chapman S Yu G Quart B Clendeninn NJ Predictors of optimal virological response to potent antiretroviral therapy Aids 1999 13 14 1873-1880 10.1097/00002030-199910010-00009 10513645
18. Yamashita TE Phair JP Munoz A Margolick JB Detels R O'Brien SJ Mellors JW Wolinsky SM Jacobson LP Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study Aids 2001 15 6 735-746 10.1097/00002030-200104130-00009 11371688
19. Kilaru KR Kumar A Sippy N Carter AO Roach TC Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country HIV Med 2006 7 2 99-104 10.1111/j.1468-1293.2006.00347.x 16420254
20. Miller V Staszewski S Boucher CA Phair JP Clinical experience with non-nucleoside reverse transcriptase inhibitors Aids 1997 11 Suppl A S157-64 9451980
21. van Leeuwen R Katlama C Murphy RL Squires K Gatell J Horban A Clotet B Staszewski S van Eeden A Clumeck N Moroni M Pavia AT Schmidt RE Gonzalez-Lahoz J Montaner J Antunes F Gulick R Banhegyi D van der Valk M Reiss P van Weert L van Leth F Johnson VA Sommadossi JP Lange JM A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients Aids 2003 17 7 987-999 10.1097/00002030-200305020-00007 12700448
22. Ananworanich J Moor Z Siangphoe U Chan J Cardiello P Duncombe C Phanuphak P Ruxrungtham K Lange J Cooper DA Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs Aids 2005 19 2 185-192 10.1097/ 00002030-200501280-00011 15668544
23. Manosuthi W Sungkanuparph S Thakkinstian A Rattanasiri S Chaovavanich A Prasithsirikul W Likanonsakul S Ruxrungtham K Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin Clin Infect Dis 2006 43 2 253-255 10.1086/505210 16779754
24. Oliva J Moreno S Sanz J Ribera E Molina JA Rubio R Casas E Marino A Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis Aids 2003 17 4 637-638 10.1097/ 00002030-200303070-00024 12598789
25. Geel J Pitt J Orrell CJ Van Dyk M Wood R The effect of fluconazole on nevirapine pharmacokinetics: July 11-16; Bangkok. 2004 1 369 17271687
26. Baylor MS Johann-Liang R Hepatotoxicity associated with nevirapine use J Acquir Immune Defic Syndr 2004 35 5 538-539 10.1097/ 00126334-200404150-00014 15021321
27. Sanne I Mommeja-Marin H Hinkle J Bartlett JA Lederman MM Maartens G Wakeford C Shaw A Quinn J Gish RG Rousseau F Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects J Infect Dis 2005 191 6 825-829 10.1086/428093 15717255
28. Reisler K High hepatotoxicity rate seen among HAART patients AIDS Alert 2001 16 9 118-119 1547496
29. Stern JO Robinson PA Love J Lanes S Imperiale MS Mayers DL A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients J Acquir Immune Defic Syndr 2003 34 Suppl 1 S21-33 14562855